1,387 reports of this reaction
3.7% of all DABRAFENIB reports
#4 most reported adverse reaction
FATIGUE is the #4 most commonly reported adverse reaction for DABRAFENIB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,387 FDA adverse event reports linking DABRAFENIB to FATIGUE. This represents approximately 3.7% of all 37,967 adverse event reports for this drug.
Patients taking DABRAFENIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among DABRAFENIB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for DABRAFENIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 1,387 FDA reports for DABRAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.7% of all adverse event reports for DABRAFENIB, making it a notable side effect.
If you experience fatigue while taking DABRAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.